ReviewAutoimmunity reviews2016
The role of B cells and autoantibodies in neuropsychiatric lupus.
Review in Autoimmunity reviews, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Organ-based characterization of B cells in patients with systemic lupus erythematosus.Frontiers in immunology · 2025Pooled it
- Intrathecal injection of rituximab inhibits microglial M1 polarisation to alleviate neuropsychiatric SLE symptoms via the cAMP/PKA/CREB signalling pathway.Lupus science & medicine · 2026Article
- Comparison of obinutuzumab and rituximab for treating neuropsychiatric lupus: a retrospective case-control study.Lupus science & medicine · 2025Article
- A cross-sectional study on white matter hyperitensity in patients at the initial diagnosis of neuropsychiatric SLE: Correlation with Clinical and Laboratory Findings.Clinical rheumatology · 2025Article
- Autoimmune encephalitis associated with anti-LGI1 antibody: a potential cause of neuropsychiatric systemic lupus erythematosus.Lupus science & medicine · 2025Article
- Case Report: A patient presenting primarily with psychosis of NPSLE treated with telitacicept, corticosteroids, and immunosuppressants.Frontiers in immunology · 2025Article
- Deciphering Mechanisms, Prevention Strategies, Management Plans, Medications, and Research Techniques for Strokes in Systemic Lupus Erythematosus.Medicines (Basel, Switzerland) · 2024Review
- Examination of the shared genetic architecture between multiple sclerosis and systemic lupus erythematosus facilitates discovery of novel lupus risk loci.Human genetics · 2024Article
- Pristane induced lupus mice as a model for neuropsychiatric lupus (NPSLE).Behavioral and brain functions : BBF · 2023Article
- Article
- The role of type I IFN in autoimmune and autoinflammatory diseases with CNS involvement.Frontiers in neurology · 2022Review
- Lupus animal models and neuropsychiatric implications.Clinical rheumatology · 2021Review
- Primary central nervous system lymphoma in neuropsychiatric systemic lupus erythematosus: case-based review.Rheumatology international · 2021Review
- Blood-brain barrier disruption in atrial fibrillation: a potential contributor to the increased risk of dementia and worsening of stroke outcomes?Open biology · 2021Review
- Calcium-Dependent Translocation of S100B Is Facilitated by Neurocalcin Delta.Molecules (Basel, Switzerland) · 2021Article
- Comparative proteomics analysis of plasma protein in patients with neuropsychiatric systemic lupus erythematosus.Annals of translational medicine · 2020Article
- Leptin: an unappreciated key player in SLE.Clinical rheumatology · 2020Review
- Early and Short-Term Interventions in the Gut Microbiota Affects Lupus Severity, Progression, and Treatment in MRL/lpr Mice.Frontiers in microbiology · 2020Article
- Shared development of targeted therapies among autoimmune and inflammatory diseases: a systematic repurposing analysis.Therapeutic advances in musculoskeletal disease · 2020Article
- The SLE-key test serological signature: new insights into the course of lupus.Rheumatology (Oxford, England) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The central nervous system manifestations of SLE (neuropsychiatric lupus, NPSLE) occur frequently, though are often difficult to diagnose and treat. Symptoms of NPSLE can be quite diverse, including chronic cognitive and emotional manifestations, as well as acute presentations, such as stroke and seizures. Although the pathogenesis of NPSLE has yet to be well characterized, B-cell mediated damage is believed to be an important contributor. B-cells and autoantibodies may traverse the blood brain barrier promoting an inflammatory environment consisting of glia activation, neurodegeneration, and consequent averse behavioral outcomes. This review will evaluate the various suggested roles of B-cells and autoantibodies in NPSLE, as well as therapeutic modalities targeting these pathogenic mediators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.